QC
SYRE icon

Quadrature Capital’s Spyre Therapeutics SYRE Stock Holding History

Quadrature Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,366
Closed -$325K – 1640
2025
Q3 		$325K Buy
+19,366
New +$316K ﹤0.01% 648

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Quadrature Capital's SYRE Position: Q4 2025 in Review

Quadrature Capital sold out of Spyre Therapeutics (SYRE) in Q4 2025, closing a stake of 19,366 shares — an estimated $325K sold.

Quadrature Capital first reported a position in SYRE in Q3 2025 and held it in 1 quarter. The position peaked at $325K in Q3 2025. 153 funds tracked by Wall St. Rank hold SYRE as of Q4 2025.

  • Quadrature Capital reported no remaining Spyre Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Quadrature Capital sold 19,366 Spyre Therapeutics shares in Q4 2025, an estimated $325K.
  • Quadrature Capital first reported a position in Spyre Therapeutics in Q3 2025 and held it in 1 quarter.
  • Quadrature Capital's Spyre Therapeutics position peaked at $325K in Q3 2025.
  • 153 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.